glp-1 obesity drugs news today 2025 Pharmacy Pricing Update (Dec 2025) glp-1 obesity drug news today
Description
In consideration of the reduced compliance of peptide GLP-1 receptor agonists due to subcutaneous injection, oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity (Wharton et al 2023) (Fig
Recent studies have shown that GLP-1R also exists in the DMH while co-expressing leptin receptors (LepR) [58]
Researchers are still exploring the link between protein and GLP-1 production, and more human studies are ultimately needed
Increasing data are showing that weight loss with these medications has increased fertility
